地诺单抗国内的售价多少？

It is a drug targeting the RANK ligand. Compared with bisphosphonates that have been used clinically, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously in clinical practice and is easy to use. Moreover, clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on patient Renal function monitoring determines the speed of administration; however, denosumab is currently relatively expensive, and the balance between its long-term efficacy and cost-effectiveness needs to be further confirmed. It is expected that denosumab, a drug specifically targeting RANK ligand inhibitors, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.

In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration.

On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for Denosumab Injection (English name: Denosumab Injection). The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment.

Many patients are more concerned about the price of denosumab in China. However, since denosumab is conditionally approved for marketing in China and has not been fully popularized, the domestic price of denosumab is not very clear. According to past experience, the price of new drugs on the market in my country is relatively high, and many families often cannot afford it without medical insurance reimbursement.

Medical Travel has learned that the product produced by Amgen of the United States and marketed in Turkey is relatively cheap. The specification is 125mg/1ml tube/box, and the price is about 3,000$ equivalent to RMB. Patients in need can further contact the medical companion service to learn more about denosumab.